Novo Nordisk Canada announces appointment of new president

Béatrice Clerc named president, Canadian affiliate

Mississauga, September 13, 2019 – Novo Nordisk Canada Inc. is pleased to welcome Béatrice Clerc as the new president of the company.

Ms. Clerc is no stranger to the Novo Nordisk family, having joined the French affiliate in 2008 as Marketing Director. Most recently, Ms. Clerc was Corporate Vice President and General Manager of Novo Nordisk France, where she demonstrated her leadership by improving patient access to innovative medicines and overseeing the launch of several new therapies during her tenure.

"I look forward to continuing to build strong partnerships with policymakers, healthcare professionals, patients, and non-governmental organizations," said Ms. Clerc. "In my experience, collaboration is key to ensuring patients can access life-changing medicines."

Ms. Clerc joins Novo Nordisk Canada at an exciting time. The Canadian team has brought five innovative therapies to patients in the last two years and is committed to sustainable business practices and supporting Novo Nordisk’s ambition to have zero CO₂ emissions from operations and transportation by 2030.

Ms. Clerc comes from France where she previously worked at Schering-Plough, Sanofi and Pfizer. She received a Doctorate in Pharmacy from the Université de Caen Normandie, and her Master of Business and Administration from ESSEC.

Novo Nordisk Canada Inc. is an affiliate of Novo Nordisk A/S, a global healthcare company with more than 95 years of innovation and leadership in diabetes care, a heritage that has given Novo Nordisk the experience and capability to also help people living with hemophilia, growth disorder, obesity and other chronic conditions. As president of the Canadian affiliate, Ms. Clerc will lead a team of more than 300 professionals who are working to improve health outcomes for Canadians.
About Novo Nordisk
Novo Nordisk is a global healthcare company with more than 95 years of innovation and leadership in diabetes care. This heritage has given us experience and capabilities that also enable us to help people defeat obesity, hemophilia, growth disorders and other serious chronic diseases. Headquartered in Denmark, Novo Nordisk employs approximately 41,600 people in 80 countries and markets its products in more than 170 countries. For more information, visit novonordisk.ca, Twitter, YouTube.

Further information
Media:
Lisa Rostoks 905-206-2281  LZRO@novonordisk.com